Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

Al-Ali, Haifa Kathrin; Grießhammer, Martin; Coutre, Philipp le; Waller, Christiane; Liberati, Anna Marina; Schafhausen, Philippe; Tavares, Renato; Giraldo, Pilar; Foltz, Lynda; Raanani, Pia; Gupta, Vikas; Tannir, Bayane; Ronco, Julian Perez; Ghosh, Jagannath; Martino, Bruno; Vannucchi, Alessandro M.

doi:10.3324/haematol.2016.143677

Cited by 137 publications

(126 citation statements)

References 20 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…As with hydroxyurea, significant anemia and thrombocytopenia are the most common side effects, often requiring discontinuation [7]. However, despite the combination of ruxolitinib with a cytoreductive agent, we obtained control of leukocytosis and anemia with concurrent increase in platelet count to stable normal values, without the expected synergic cytotoxic effects.…”

mentioning

confidence: 90%

Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis

et al. 2017

View full text Add to dashboard Cite

mentioning

confidence: 90%

Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis

et al. 2017

View full text Add to dashboard Cite

“…An increased risk of lymphoproliferative disorders and other cancers has not been apparent when tofacitinib is used to treat inflammatory disorders such as RA and psoriasis 42,45,59,60 ; longer term studies, however, will more definitively answer this question. In patients with myelofibrosis and polycythemia vera treated with ruxolitinib, no increased risk of developing a second malignancy has been shown 61,62 .…”

Section: Safety Datamentioning

confidence: 99%

JAK inhibitors in dermatology: The promise of a new drug class

Damsky

King

2017

Journal of the American Academy of Dermatology

382

286

View full text Add to dashboard Cite

New molecularly targeted therapeutics are changing dermatologic therapy. JAK-STAT is an intracellular signaling pathway upon which many different pro-inflammatory signaling pathways converge. Numerous inflammatory dermatoses are driven by soluble inflammatory mediators which rely on JAK-STAT signaling, and inhibition of this pathway using JAK inhibitors may be a useful therapeutic strategy for these diseases. There is growing evidence that JAK inhibitors are efficacious in atopic dermatitis, alopecia areata, psoriasis, and vitiligo. Additional evidence suggests that JAK inhibition may be broadly useful in dermatology, with early reports of efficacy in several other conditions. JAK inhibitors can be administered orally or used topically and represent a promising new class of medications. The use of JAK inhibitors in dermatology is reviewed here.

show abstract

“…лечения. Общая вы-живаемость в течение года составила 91 %, при этом выживаемость без прогрессирования -94 % [16].…”

Section: таргетная терапия миелофиброзаunclassified

“…Ко времени анализа руксолитиниб продолжали при-нимать 88 % больных. По показателям общей выжи-ваемости (1-летняя -92 %, 2-летняя -87 %), а также частоты прогрессирования (1-летняя выживаемость без прогрессирования -94 %) мы констатировали полное совпадение собственных данных эффектив-ности руксолитиниба в рутинной клинической практике с результатами, полученными в клиниче-ских исследованиях COMFORT-I, COMFORT-II и JUMP [8,[14][15][16].…”

Section: таргетная терапия миелофиброзаunclassified

Targeted Therapy of Myelofibrosis

Vinogradova¹,

Shuvaev²,

Мартынкевич³

et al. 2017

Клиническая онкогематология

View full text Add to dashboard Cite

Background. Myelofibrosis (primary myelofibrosis, postessential trombocythemia myelofibrosis, post-polycythemia myelofibrosis) is the most complex and pressing problem among all Ph-negative myeloproliferative diseases. The present article summarizes the author's experience of using new Janus kinase inhibitors in routine clinical practice, and compares the data with the results of other clinical research. Aim. To evaluate the use of ruxolitinib in patients with myelofibrosis. Materials & Methods. Our analysis includes 48 patients (21 men and 27 women) with histologically verified myelofibrosis (primary myelofibrosis in 36 cases, post-essential trombocythemia myelofibrosis in 10 cases, and post-polycythemia myelofibrosis in 2 cases) in a chronic stage. All patients received ruxolitinib. Median age at the start of therapy was 60 years (range from 35 to 79). Massive splenomegaly (> 10 cm below the costal margin) was found in 34 (71 %) of 48 patients. The initial dose of ruxolitinib was determined by the platelet level. The efficacy of the therapy was evaluated in accordance with ELN 2013 criteria. Results. Median duration of treatment was 18 months (range from 1 to 50 months). Symptoms of intoxication were relieved in 33 of 37 patients (89 %). The spleen size decreased in 64 % of patients. In 33 % of cases spleen size did not change, whereas an increase was observed in 3 % of patients. In the majority of patients hemoglobin level remained stable through the course of treatment. Three of 14 transfusion dependent patients did not require blood transfusions after 3 months of therapy. In patients with high thrombocyte levels prior to ruxolitinib therapy the mean level was approaching normal by the end of the 1st month of treatment. The median JAK2V617F mutant allele burden at the beginning treatment was 56.5 % (n = 20; 22.5-126.1 %). After 6 moths of treatment it accounted for 62.3 % (n = 11; 25.4-79.7 %) and in 12 months accounted for 47.4 % (n = 12; 14.2-102.2 %). By the time of the analysis 42 of 48 patients continued the ruxolitinib treatment (88 %). Death occurred in 4 patients. Overall 1-year (92 %) and 2-year (87 %) survival corresponds to the data of COMFORT-I, COMFORT-II and JUMP clinical trials. Conclusion. Ruxolitinib showed to be an effective treatment for myelofibrosis. The most pronounced and rapid effect ruxolitinib had on the spleen size and the symptoms of intoxication. The tolerability of ruxolitinib was satisfactory in the majority of patients. According to the author's data, ruxolitinib had a small impact on the JAK2V617F mutant allele burden. The overall survival rate in patients with myelofibrosis, receiving ruxolitinib in the clinical setting was similar to that of in the clinical trials.

show abstract

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

Cited by 137 publications

References 20 publications

Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis

Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis

JAK inhibitors in dermatology: The promise of a new drug class

Targeted Therapy of Myelofibrosis

Contact Info

Product

Resources

About